Bli medlem
Bli medlem

Du är här


Zealand Pharma: Zealand increases its share capital as a consequence of exercise of employee warrants

Company announcement - No. 45 / 2016

Zealand increases its share capital as a consequence of exercise of employee

Copenhagen, 17 November 2016
- Zealand Pharma ("Zealand") has increased its share capital with nominal DKK
8,200 divided into 8,200 new shares with a nominal value of DKK 1 each. The
increase is a consequence of the exercise of warrants granted under one of
Zealand's employee warrant programs.

Employee warrant programs are part of Zealand's incentive scheme, and each
warrant gives the owner the right to subscribe for one new Zealand share at a
pre-specified price, the exercise price, in specific pre-defined time periods
before expiration. For further description of Zealand's warrant programs, see
the company's Articles of Association, which are available on the

The exercise price is DKK 77 per share and the total proceeds to Zealand from
the capital increase amounts to DKK 631,400.

The new shares give rights to dividend and other rights from the time of the
warrant holder's exercise notice. Each new share carries one vote at
Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the
capital increase with the Danish Business Authority. Following registration
of the new shares, the share capital of Zealand will be nominal DKK
26,070,453 divided into 26,070,453 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share
capital increase has today been registered with the Danish Business


For further information, please contact:

Mats Blom,
Senior Vice President, Chief Financial Officer

Tel: +45
31 53 79 73, email:

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery, design and development of innovative
peptide-based medicines. Zealand has a portfolio of medicines and product
candidates under license collaborations with Sanofi, Boehringer Ingelheim and
Helsinn and a pipeline of proprietary product candidates, which primarily
target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial
GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi.
Lixisenatide is marketed as Lyxumia®outside the United States and approved as
AdlyxinTMin the United States. Lixisenatide has been developed in a
fixed-ratio combination with Lantus®(insulin glargine) which product is under
regulatory review in the United States and in Europe.

Zealand's proprietary pipeline includes:Dasiglucagon*(ZP4207) as single-dose
rescue treatment
for acute, severe hypoglycemia (Phase II);Glepaglutide* (ZP1848)
for treatment of short bowel syndrome (Phase II);Dasiglucagon* (ZP4207)
multiple-dose version
intended for use in a dual-hormone artificial pancreas system for better
hypoglycemia control and diabetes management (in preparation for Phase II);
and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information
about the company's business and activities, please visit or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary
Names (pINN)

45-16_1117 Warrant exercise and capital increase

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.